348 related articles for article (PubMed ID: 8749635)
1. Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review.
Lamothe F; D'Amico P; Ghosn P; Tremblay C; Braidy J; Patenaude JV
Clin Infect Dis; 1995 Dec; 21(6):1469-70. PubMed ID: 8749635
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review.
Cawley MJ; Briggs M; Haith LR; Reilly KJ; Guilday RE; Braxton GR; Patton ML
Pharmacotherapy; 1999 Sep; 19(9):1094-8. PubMed ID: 10610017
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic considerations for children with invasive group a streptococcal infections: a case series report and review of the literature.
Burnett AM; Domachowske JB
Clin Pediatr (Phila); 2007 Jul; 46(6):550-5. PubMed ID: 17579110
[No Abstract] [Full Text] [Related]
4. Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature.
Crum NF; Wallace MR
Scand J Infect Dis; 2003; 35(11-12):878-81. PubMed ID: 14723367
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.
Perez CM; Kubak BM; Cryer HG; Salehmugodam S; Vespa P; Farmer D
Am J Med; 1997 Jan; 102(1):111-3. PubMed ID: 9209207
[No Abstract] [Full Text] [Related]
6. Group A Streptococcus invasive infections: a review.
Weiss KA; Laverdière M
Can J Surg; 1997 Feb; 40(1):18-25. PubMed ID: 9030079
[TBL] [Abstract][Full Text] [Related]
7. Necrotizing fasciitis and myositis caused by streptococcal flesh-eating bacteria.
García-Casares E; Mateo Soria L; García-Melchor E; Riera Alonso E; Olivé Marqués A; Holgado Pérez S; Tena Marsà X; Molinos Abós S
J Clin Rheumatol; 2010 Dec; 16(8):382-4. PubMed ID: 21085016
[TBL] [Abstract][Full Text] [Related]
8. [Necrotizing fasciitis of the eyelids and toxic shock syndrome due to Streptococcus pyogenes].
Bustos B R; Soto G G; Hickmann O L; Torres B C
Rev Chilena Infectol; 2009 Apr; 26(2):152-5. PubMed ID: 19621147
[TBL] [Abstract][Full Text] [Related]
9. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment.
Stevens DL
Emerg Infect Dis; 1995; 1(3):69-78. PubMed ID: 8903167
[TBL] [Abstract][Full Text] [Related]
10. Necrotizing fasciitis.
Cherneski CL; Embil JM
Saudi Med J; 2001 Jul; 22(7):565-8. PubMed ID: 11479634
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and treatment of streptococcal toxic shock syndrome.
Tachi M; Hirabayashi S; Harada H; Nishio T
Scand J Plast Reconstr Surg Hand Surg; 2002; 36(5):305-8. PubMed ID: 12477090
[TBL] [Abstract][Full Text] [Related]
12. Dilemmas in the treatment of invasive Streptococcus pyogenes infections.
Stevens DL
Clin Infect Dis; 2003 Aug; 37(3):341-3. PubMed ID: 12884157
[No Abstract] [Full Text] [Related]
13. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.
Stevens DL
Clin Infect Dis; 1998 Mar; 26(3):639-41. PubMed ID: 9524836
[No Abstract] [Full Text] [Related]
14. Group A streptococcal infections. An old adversary reemerging with new tricks?
Feingold DS; Weinberg AN
Arch Dermatol; 1996 Jan; 132(1):67-70. PubMed ID: 8546486
[No Abstract] [Full Text] [Related]
15. Invasive group A streptococcal infections: the past, present and future.
Stevens DL
Pediatr Infect Dis J; 1994 Jun; 13(6):561-6. PubMed ID: 8078755
[No Abstract] [Full Text] [Related]
16. Intravenous immunoglobulin therapy for toxic shock syndrome.
Barry W; Hudgins L; Donta ST; Pesanti EL
JAMA; 1992 Jun; 267(24):3315-6. PubMed ID: 1597914
[TBL] [Abstract][Full Text] [Related]
17. Necrotizing myositis case report and brief literature study.
Basso A; Moerman F; Ronsmans C; Demarche M
Acta Clin Belg; 2020 Dec; 75(6):424-428. PubMed ID: 31268407
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
Linnér A; Darenberg J; Sjölin J; Henriques-Normark B; Norrby-Teglund A
Clin Infect Dis; 2014 Sep; 59(6):851-7. PubMed ID: 24928291
[TBL] [Abstract][Full Text] [Related]
19. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach.
Norrby-Teglund A; Muller MP; Mcgeer A; Gan BS; Guru V; Bohnen J; Thulin P; Low DE
Scand J Infect Dis; 2005; 37(3):166-72. PubMed ID: 15849047
[TBL] [Abstract][Full Text] [Related]
20. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund A; Low DE; McGeer A; Kotb M
Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
